Oric Pharmaceuticals (ORIC)

• Market cap: $735M
• 1 day: -3.25%
• 5 days: 2.26%
• 1 month: 29.12%
• 3 months: 11.09%
• 6 months: -6.96%
• Year to date: 26.15%
• 1 year: -5.19%
• 5 years: -59.57%
• 10 years: -59.57%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Employees: 112

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,838% more call options, than puts

Call options by funds: $155K | Put options by funds: $8K

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

49% more capital invested

Capital invested by funds: $481M [Q2] → $715M (+$234M) [Q3]

9% more funds holding

Funds holding: 112 [Q2] → 122 (+10) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 38

1.88% less ownership

Funds ownership: 100.92% [Q2] → 99.04% (-1.88%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $21 102% upside
• Avg. target: $21 102% upside
• High target: $21 102% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 33% 1-year accuracy 54 / 165 met price target

102% upside $21

Buy Reiterated

13 Jan 2025